В настоящее время наиболее эффективными препаратами для лечения и достижения контроля над бронхиальной астмой (БА) являются ингаляционные глюкокортикостероиды (ИГКС), назначение которых, согласно международным рекомендациям, показано при персистирующей БА любой степени тяжести в качестве стартовой терапии [ 10].
Геппе Н.А., Шаталина С.И., Колосова Н.Г., Машукова Н.П, Малышев В.С. Комбинированный препарат будесонид/формотерол в контроле обострений бронхиальной астмы у детей. Доктор.ру. 2013, 3: 16-24.
Геппе Н.А., Бераиа Т.Т. Ингаляционные глюко-кортикостероиды в терапии бронхиальной астмы у детей. Cons. Med. Педиатрия. 2008. 1: 50-3.
Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». М., 2012, 180с.
AaLbers et aL. Protective effect of budesonide/ formoteroL compared with formoteroL, saLbuta-moL and pLacebo on repeated provocations with inhaLed AMP in patients with asthma: a randomised, doubLe-bLind, cross-over study. Respiratory Research. 2010, 11:66.
Agertoft L, Pedersen S. Bone mineraL density in chiLdren with asthma receiving Long-term treatment with inhaLed budesonide. Am J Respir Crit Care Med. 1998. Jan. 157(1):178-83.
Agertoft L, Pedersen S. Effect of Long-term treatment with inhaLed budesonide on aduLt height in chiLdren with asthma. N Engl J Med. 2000 Oct 12. 343(15):1064-9.
Brattsand R et aL. The roLe of intraceLLuLar esterification in budesonide once-daiLy dosing and airway seLectivity. Clin. Ther. 2003. VoL. 25 SuppL. C.P. S28-41.
Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, TownLey RG. Budesonide deLivered by TurbuhaLer is effective in a dose-dependent fashion when used in the treatment of aduLt patients with chronic asthma. J Allergy Clin Immunol. 1998 Apr. 101(4 Pt 1):457-63.
Camargo CA et aL. Association between common asthma therapies and recurrent asthma exacerbations in chiLdren enroLLed in a state Medicaid pLan. Am J Health Syst Pharm. 2007 May 15;64(10):1054-61.
GLobaL Strategy for Asthma Management and Prevention. GLobaL Initiative for Asthma (GINA); 2014. GLobaL Initiative for Asthma.http//www. ginasthma.org
Horvath G, Wanner A. InhaLed corticosteroids: effects on the airway vascuLature in bronchiaL asthma. Eur Respir J. 2006 Jan. 27(1):172-87.
MiLLer-Larsson A et aL. ProLonged Airway Activity and Improved SeLectivity of Budesonide PossibLy Due To Esterification. Am. J. Respir. Crit. Care Med. 2000. 162: 1455-1461.
PapadopouLos NG. et aL. InternationaL consensus on (ICON) pediatric asthma. Allergy, 2012. VoL. 67. 8: 976-997.
Peter G. Gibson, NicoLas SaLtos, and K. Fakes Acute Anti-infLammatory Effects of InhaLed Budesonide in Asthma A Randomized ControLLed TriaL. Am J Respir Crit Care Med, 2001. 163: 32-36.
TaL A et aL. Budesonide/formoteroL in a singLe inhaLer versus inhaLed corticosteroids aLone in the treatment of asthma. Pediatr Pulmonol. 2002 Nov. 34(5):342-50.
Geppe N.A., Shatalina S.I., Kolosova N.G., Mashukova N.G., Malyshev V.S. Combination drug budesonide/formoterol in the management of bronchial asthma exacerbations in children. Doktor.Ru. 2013, 3: 16-24.
Geppe N.A., Kolosova N.G., Denisova A.R. [et al]. The effectiveness of combination therapy of bronchial asthma in children in everyday outpatient practice. Meditsinskiy Sovet, 2014, 14: 50-56.
National program "Bronchial asthma in children. Treatment strategy and prevention". М., 2012, 180 p.